Thomas K. Equels

All filings by Thomas K. Equels on record concern AIM ImmunoTech Inc., in the capacity of chief executive. Over a trading history stretching from 16 July 2021 to 17 September 2026, the count stands at 38 filings.

The open-market record is one-sided, with 26 purchases worth €287k and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 11 share grants. In 2026 alone, the filings show 4 purchases and no sales.

Half of the purchases are above €5,947 and half below. Relative to company size, the median is 0.043% of market cap (4 purchases with a known value). Of 26 purchases, 8 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The record was last updated on 18 September 2026 with an open-market purchase (€4,355) in AIM ImmunoTech Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.